Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study-Reference-Cited by-同舟云学术

Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study

Published:2016 Issue:12 Volume:39 Page:2060-2065
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Ide Kazuki¹²³,Sato Izumi²⁴,Imai Takumi²,Hawke Philip⁵,Yamada Hiroshi¹,Kawasaki Yohei¹,Masaki Naohiko⁶

Affiliation:

1. Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka

2. Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University

3. Center for the Promotion of Interdisciplinary Education and Research, Kyoto University

4. Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine

5. Department of Scientific English, Graduate School of Pharmaceutical Sciences, University of Shizuoka

6. The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/39/12/39_b16-00617/_pdf

Reference20 articles.

1. 1) World Health Organization. “Hepatitis C. Fact sheet No. 164.”: ‹http://www.who.int/mediacentre/factsheets/fs164/en/〉, cited 28 July, 2016.

2. 2) Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med., 368, 34–44 (2013).

3. 3) Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet, 383, 515–523 (2014).

4. 4) Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo HM, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis., 15, 645–653 (2015).

5. 5) Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology, 146, 1176–1192 (2014).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study;Biological & Pharmaceutical Bulletin;2017